Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019[Formula presented]

S Gillessen; G Attard; TM Beer; H Beltran; A Bjartell; A Bossi; A Briganti; RG Bristow; KN Chi; N Clarke; ID Davis; J de Bono; CG Drake; I Duran; R Eeles; E Efstathiou; CP Evans; S Fanti; FY Feng; K Fizazi; M Frydenberg; M Gleave; S Halabi; A Heidenreich; D Heinrich; CS Higano; MS Hofman; M Hussain; N James; R Kanesvaran; P Kantoff; RB Khauli; R Leibowitz; C Logothetis; F Maluf; R Millman; AK Morgans; MJ Morris; N Mottet; H Mrabti; DG Murphy; V Murthy; WK Oh; P Ost; JM O'Sullivan; AR Padhani; C Parker; DMC Poon; CC Pritchard; RE Reiter; M Roach; M Rubin; CJ Ryan; F Saad; JP Sade; O Sartor; HI Scher; N Shore; E Small; M Smith; H Soule; CN Sternberg; T Steuber; H Suzuki; C Sweeney; MR Sydes; ME Taplin; B Tombal; L Türkeri; I van Oort; A Zapatero; A Omlin

Journal article

Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019[Formula presented]

S Gillessen, G Attard, TM Beer, H Beltran, A Bjartell, A Bossi, A Briganti, RG Bristow, KN Chi, N Clarke, ID Davis, J de Bono, CG Drake, I Duran, R Eeles, E Efstathiou, CP Evans, S Fanti, FY Feng, K Fizazi Show all

European Urology | ELSEVIER | Published : 2020

DOI: 10.1016/j.eururo.2020.01.012

Abstract

At the Advanced Prostate Cancer Consensus Conference (APCCC) 2019, 10 important areas of controversy in advanced prostate cancer management were identified and discussed, and experts voted on 123 predefined consensus questions. The full report of the results is summarised here.

University of Melbourne Researchers

Declan Murphy Author

Grants

Awarded by Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung

Funding Acknowledgements

We gratefully acknowledge the following organisations for providing financial support for the APCCC 2019: Canton of Basel, European School of Oncology (ESO), Swiss Cancer League, Swiss Oncology Research Network (SAKK), Prostate Cancer Foundation (PCF), and Cantonal Hospital St. Gallen. We would like to especially thank the Movember Foundation for generously supporting the APCCC 2019. Special thanks also to the EAU, the European Organisation for Research and Treatment of Cancer (EORTC), the European Society for Radiotherapy and Oncology (ESTRO), and the European School of Oncology (ESO) for their endorsements. We also acknowledge sponsorship from several for-profit organisations, including Astellas, Bayer Health Care, AstraZeneca, MSD, Pfizer Oncology, Janssen Oncology, Sanofi Genzyme, Amgen, Clovis Oncology, Ferring Pharmaceuticals, Ipsen, Roche, Tolmar, Advanced Accelerator Applications, and Orion Pharma (details on sponsorship are available at www.apccc.org).These for-profit organisations supported the conference financially but had no input on the scientific content or the final publication. Ian D. Davis is supported by a National Health and Medical Research Council (NHMRC) Practitioner Fellowship (APP1102604). Michael S. Hofman is supported by a clinical fellowship award from the Peter MacCallum Foundation.